WORCESTER -
The data were presented during a poster session on
All nine patients have responded clinically to treatment in this multicenter trial and the safety and efficacy profile of MB-106 appears to be consistent with the original single-institution trial. It is especially encouraging that complete responses were observed in all patients with follicular lymphoma in this multicenter trial, said
Highlights from the data include: All patients responded clinically to treatment with MB-106 (n=9); 100% overall response rate for patients with follicular lymphoma ( FL ) and Waldenstrom macroglobulinemia ( WM )
100% of patients with FL (n=5) had a complete response; 1 very good partial response and 2 partial responses were observed in WM patients (n=3) and the hairy cell leukemia variant ( HCL-v ) patient experienced stable disease, with prolonged, ongoing independence from blood transfusions
Complete responses observed in patients previously treated with CD19-targeted CAR T-cell therapy
MB-106 has a tolerable safety profile in patients with indolent NHL, with no occurrence of CRS above grade 1, and no ICANS of any grade, despite not using prophylactic tocilizumab or dexamethasone
Outpatient administration was allowed and found to be feasible
MB-106 CAR T-cell expansion and persistence in patients was demonstrated
About
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as anticipate, believe, could, estimate, expect, goal, intend, look forward to, may, plan, potential, predict, project, should, will, would and similar expressions. The Company s forward-looking statements, include, but are not limited to, any statements relating to our growth strategy and product development programs, including the timing of and our ability to make regulatory filings such as INDs and other applications and to obtain regulatory approvals for our product candidates, statements concerning the potential of therapies and product candidates and any other statements that are not historical facts. Actual events or results may differ materially from those described in this press release due to a number of risks and uncertainties. Risks and uncertainties include, among other things, risks related to the satisfaction of the conditions necessary to transfer the lease of the Company s manufacturing facility and receive the contingent payment in connection with the Company s sale of its manufacturing facility in the anticipated timeframe or at all; whether the purchaser of the Company s manufacturing facility is able to successfully perform its obligation to produce the Company s products under the manufacturing services agreement on a timely basis and to acceptable standards; disruption from the sale of the Company s manufacturing facility making it more difficult to maintain business and operational relationships; negative effects of the announcement or the consummation of the transaction on the market price of the Company s common stock; significant transaction costs; the development stage of the Company s primary product candidates, our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in Part I, Item 1A, Risk Factors, in our Annual Report on Form 10-K filed on
Contact:
Tel: (781) 652-4500
Email: ir@mustangbio.com
(C) 2023 Electronic News Publishing, source